Using Health-related Quality of Life (HRQL) in Routine Clinical Care
An Assessment of the Effects of the Use of Measures of Health-related Quality of Life in Routine Clinical Care:an Application to Lung Transplantation.
The objective of this study is to assess the effects of using HRQL measures in the clinical care of pre- and post-lung transplant patients.
The hypotheses are that the inclusion of HRQL measures, the Health Utilities Index System Mark 2(HUI2) and Mark 3 (HUI3), in routine clinical care of pre- and post-lung transplant patients, will: 1) improve patient-clinician communication;2) affect patient management; 3) improve patients' HRQL.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Recently there has been increasing interest in the use of health-related quality of life (HRQL) measures in routine clinical practice. Traditionally, patient care has been based on laboratory results, medical history, and signs and symptoms diagnosed by clinicians. The inclusion of HRQL measures in routine practice may provide important and often otherwise missing information, revealing the impact of the disease or its treatment on the patient's physical, emotional and social well-being, and may assist in patient management. HRQL assessments may assist in changing the medical paradigm from a disease-centered approach to a patient-centered one.
Several studies in mental health and oncology discuss the application of HRQL measures in clinical practice. Taenzer et al (2000) and Detmar et al. (2002) provide evidence that using HRQL measures improves patient-clinician communication. Velikova et al (2004) detected impacts on communication and the emotional well-being of patients.
Using a framework based on these previous studies and the methods for the health technology assessment of diagnostic technologies (Guyatt et al. 1986), we will assess the effects of including HRQL assessments in the routine clinical care of patients undergoing solid organ transplantation (lung).
We expect that the routine use of HRQL measures in clinical practice will affect patient-clinician communication, patient management, and patient outcome.
Lung transplantation trades a fatal disease (end-stage pulmonary disease) for a chance at prolonged survival and improved quality of life, albeit with immunosuppression. In this context, generic preference-based measures such as HUI2 and HUI3 are preferred to specific measures, because they measure a broader range of health dimensions, including pain, ambulation and emotional issues that are expected to be relevant. Preference-based measures provide scores on the conventional 0.00 (dead) to 1.00 (perfect health) scale that allows for the integration of morbidity and mortality effects and calculation of quality adjusted life years (QALYs) and health-adjusted life expectancy (HALE).
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Alberta
-
Edmonton, Alberta, Kanada
- University of Alberta Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- pre-lung transplant:subjects who are included on the waiting list and are being seen at the out-patient clinic
- post-lung transplant subjects.
Exclusion Criteria:
- younger than 18 years of age
- diagnosed as being cognitively impaired
- unable to complete questionnaires in English
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Ohjaus
|
Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card.
Clinicians used the HUI score card as an extra tool to help them in the management of the patients
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Communication Score
Aikaikkuna: Baseline and end of study (6 months)
|
Each clinician-patient encounter was audio tape-recorded.
The content of the tape-recordings was examined and results recorded on the communication form by three blinded raters.
This form tallies the number of issues discussed.
The number of issues is summed to produce a communication score.
The issues discussed included health attributes included in the HUI2 and HUI3: ambulation, self-care, anxiety, depression, cognitive problems, pain (type and frequency), vision, hearing speech and dexterity problems.
|
Baseline and end of study (6 months)
|
|
Management Composite
Aikaikkuna: At baseline and end of study (6 months)
|
Changes in clinical management were recorded in the chart review form.
The number of referrals to other healthcare providers, tests ordered (X-rays, blood test, bronchoscopies) and changes in medication (reduction or increase dosage, addition or discontinuation) were summed to produce the management composite.
|
At baseline and end of study (6 months)
|
|
EuroQol, EQ-5D.
Aikaikkuna: At baseline and end of study (6 months).
|
Generic preference-based measure.
EQ-5D consists of two sections: a 100-point visual analog scale (VAS) and a descriptive system that contains five attributes (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with three levels per attribute ("no problem", "some problems" and "extreme problems").Using the US scoring function EQ-5D index scores range from -0.11 (all-worst health state, worse than dead), to 0.00 (dead) to 1.00 (perfect health).
The EQ-5D is easy to complete, valid and reliable.
|
At baseline and end of study (6 months).
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
The Hospital Anxiety and Depression Scale,HADS. Completed at Baseline and End of the Study.
Aikaikkuna: Baseline and end of study (6 months)
|
HADS is a self-complete mental health measure.
The scale consists of 14 items, seven of which assess anxiety and seven which assess depression.
Each item is on a four point scale and the scores are added to give a total ranging from 0 to 21 for anxiety and 0 to 21 for depression.
Higher scores indicate more severe anxiety or depression.
A cut-point of 8 or 9 indicates mild burden for the two scales; 11 or 12 indicates severe .
All the patients completed HADS at baseline and at the end of the study.
|
Baseline and end of study (6 months)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: David H Feeny, PhD, Professor Economics, University of Alberta
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Ruoansulatuskanavan sairaudet
- Patologiset prosessit
- Sydän-ja verisuonitaudit
- Verisuonisairaudet
- Hengityselinten sairaudet
- Keuhkosairaudet
- Vauva, vastasyntynyt, sairaudet
- Geneettiset sairaudet, synnynnäiset
- Haiman sairaudet
- Hypertensio
- Fibroosi
- Keuhkosairaudet, obstruktiiviset
- Keuhkosairaus, krooninen obstruktiivinen
- Keuhkofibroosi
- Kystinen fibroosi
- Hypertensio, keuhko
Muut tutkimustunnusnumerot
- IHE-188
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .